News
FDA approves Pfizer/Merck KGaA combo in advanced colorectal ...
The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the d
